Pyranone Compounds Modulating OMA1 Protease for Mitochondrial Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapeutic interventions for mitochondrial disorders and diseases related to mitochondrial dysfunction and OPA1 alterations, with no established methods for treatment, prevention, or amelioration.
Innovation Solution
Administration of compounds capable of modulating OMA1 activity and oligomeric complexes comprising OMA1, HIGD1A, OPA1, BNIP3, YMEIL1, PHB, SAMM50, and IMMT to treat and prevent mitochondrial disorders by adjusting the activity of these proteins, which are associated with mitochondrial stress and dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are administered to modulate OMA1 activity, then therapeutic intervention for mitochondrial disorders is achieved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate OMA1 protease activity. These compounds act as mediators between the therapeutic goal and the molecular target, simplifying the treatment approach by using orally available small molecules rather than complex biologics or gene therapy approaches.
Solution Approach 2:
The patent modulates the activity of OMA1 protease by administering compounds that change the functional state of the enzyme. This involves altering the kinetic parameters of OMA1 through competitive inhibition or allosteric modulation, providing a controllable and reversible therapeutic mechanism.
2Reliability
If OMA1 activity is modulated to treat mitochondrial disorders, then disease amelioration is achieved, but the mechanism of action becomes more complex
Solution Approach 1:
The patent extracts and targets the specific function of OMA1 protease in mitochondrial dynamics by designing compounds that selectively inhibit this enzyme. This isolates the therapeutic action to a single molecular target, simplifying the mechanism despite the complex downstream effects on mitochondrial function.
Solution Approach 2:
Instead of attempting to directly restore mitochondrial function through complex interventions, the patent inverts the approach by inhibiting the protease that causes mitochondrial dysfunction. This indirect approach simplifies the mechanism by targeting the upstream cause rather than downstream effects.
Data Source
AI summary
Means and methods for therapeutic intervention of mitochondrial disorders or diseases, and in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial stress or dysfunction, a mitochondrial disorder or disease, or a disorder or disease characterized by OPA1 alterations. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of OMA1 and/or an oligomeric complex of OMA1 is administered to a patient in need of medical intervention. Methods of screening for a compound capable of modulating the activity of OMA1 and/or an oligomeric complex comprising OMA1 are performed. Methods for determining the susceptibility for, predisposition for, or the presence of such a disorder or disease and whether a person in need will benefit from the therapeutic intervention, i.e., personalized medicine are also performed.